Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$0.99 USD
+0.01 (1.02%)
Updated Sep 23, 2024 03:58 PM ET
After-Market: $1.01 +0.02 (2.02%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth C Momentum C VGM
Price, Consensus and EPS Surprise
CYCC 0.99 +0.01(1.02%)
Will CYCC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CYCC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CYCC
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates
CYCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
Other News for CYCC
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
Cyclacel files an appeal to Nasdaq delisting letter
Cyclacel Pharmaceuticals confirms filing of appeal to Nasdaq delisting letter
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket